Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.

Moon SJ; Berger AS; Tolentino MJMisch DM

首页> 外文期刊>Ophthalmic surgery, lasers & imaging: the official journal of the International Society for Imaging in the Eye >Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.

【24h】

Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.

机译：Intravitreal贝伐单抗的黄斑水肿特发性juxtafoveal视网膜毛细管扩张。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

To assess the potential visual benefit of intravitreal bevacizumab in a patient with idiopathic juxtafoveal retinal telangiectasis refractory to focal laser treatment, an intravitreal injection of bevacizumab (1.25 mg) was given. Within 1 week, visual acuity improved from 20/50 to 20/25 and optical coherence tomography demonstrated complete resolution of macular edema. There was no adverse effect. The macular edema recurred after 3 months, requiring a repeat injection of bevacizumab with subsequent resolution of macular edema. An intravitreal injection of bevacizumab may provide potential short-term visual benefit in patients with macular edema from idiopathic juxtafoveal retinal telangiectasis.

机译：评估潜在的视觉的好处intravitreal贝伐单抗的患者特发性juxtafoveal视网膜毛细管扩张耐火材料焦激光治疗,intravitreal注射贝伐单抗(1.25毫克)给出了。从20/50到20/25,光学相干断层扫描显示完整的解决黄斑水肿。黄斑水肿3个月后复发,需要贝伐单抗与后续的重复注射解决黄斑水肿。注射贝伐单抗可能提供的潜力短期视觉患者受益从特发性juxtafoveal视网膜黄斑水肿毛细管扩张。

著录项

来源
《Ophthalmic surgery, lasers & imaging: the official journal of the International Society for Imaging in the Eye》 |2007年第2期|164-166|共3页
作者
Moon SJ; Berger AS; Tolentino MJMisch DM;
展开▼
作者单位

Center for Retina and Macular Disease, Winter Haven, Florida, 33880, USA. International Society for Imaging in the Eye;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类眼科学;
关键词
Idiopathic Juxtafoveal Retinal Telangiectasia; Macular Edema; Intravitreal Injectionsmacular edemaBevacizumabAngiogenesis InhibitorsRetinal TelangiectasisMonoclonal Antibodies;

机译：特发性Juxtafoveal视网膜Telangiectasia Macular水肿;IntravitrealInjectionsmacular edemaBevacizumabAngiogenesisInhibitorsRetinal TelangiectasisMonoclonal抗体;

相似文献

外文文献
中文文献

1. Efficacy of intravitreal injection of ranibizumab in the treatment of macular edema secondary to non-ischemic branch retinal vein occlusion [J] . Jue Liu, Zai-Hong Chen 海南医科大学学报（英文版） . 2020,第002期
2. Efficacy of intravitreal injection of ranibizumab in the treatment of macular edema secondary to non-ischemic branch retinal vein occlusion [J] . Jue Liu, Zai-Hong Chen 海南医科大学学报(英文版) . 2020,第002期
3. Intravitreal Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion in Chinese Patients [J] . Jia-Kang Wang, Tzu-Lun Huang, Pei-Yuan Su, 眼科学报（英文版） . 2015,第002期
4. Telangiectasia retiniana justafoveolar idiopática do grupo 2A: hiperpigmentação macular incomum em dois pacientes Idiopathic juxtafoveolar retinal telangiectasis group 2A: an unusual macular hyperpigmentation in two patients [O] . Maria Teresa Brizzi C. Bonanomi, Fernando Betty Cresta, Suel Abujamra 2001

机译：Telangiectasia retinianajustafoveolaridiopáticadogrupo 2a：hiperpigmentaçãomacularincomum em dois pacientes Idiopathic juxtafoveolar retinal telangiectasis group 2a：两名患者出现不寻常的黄斑色素沉着过度

Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis.

摘要

著录项

相似文献

相关主题

期刊订阅